News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sucampo to Present Data on AMITIZA® (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology


9/13/2013 9:23:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Sucampo AG ("SAG"), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), announced today that it will present four posters evaluating the overall efficacy and tolerability of AMITIZA® (lubiprostone) as a treatment for chronic idiopathic constipation (CIC). These posters contain data demonstrating the efficacy and tolerability of AMITIZA regardless of age, gender, and race, a pooled analysis of the most frequent adverse events associated with AMITIZA, and an evaluation of the efficacy of AMITIZA in patients suffering from refractory constipation. Sucampo will present these data during the Annual Meeting of the Swiss Society of Gastroenterology in Basel, Switzerland on Friday, September 13, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES